Objective: To provide further short-term (6 mo) and long-term (1 y) evidence for the use of spinal cord stimulation (SCS) with a conventional implantable pulse generator in the management of chronic, intractable pain.
A dvances in the design and complexity of spinal cord stimulation (SCS) devices have led to the introduction of many new and improved systems. Original devices used to treat pain were developed on the basis of the technology of early cardiac pacemakers. These devices were initially radiofrequency-activated passive systems, with hardwired contact combinations. 1 Today's devices incorporate programmable electrode configurations and both rechargeable and primary cell batteries.
The exact mechanism by which SCS produces its effect remains unknown. SCS produces a sensation called paresthesias. It has been demonstrated that unless the paresthesias cover the area of pain, no pain relief will occur. 2, 3 The exact location of the electrode lead within the epidural space determines the location of paresthesias. The need to control the location and intensity of paresthesia coverage has driven extensive research and development in the area of lead and pulse generator manufacturing. To program and activate multiple leads, power sources have been becoming larger. To overcome this, rechargeable generators capable of producing high outputs over long periods of time without the need for replacements were developed. Such generators are capable of programming up to 16 electrode contacts.
However, there remain a number of patients in whom lower power and fewer electrodes are required to achieve a successful outcome. Such patients may derive similar benefits from simpler SCS systems with primary cell batteries and simple electrode configurations.
In the patient population for whom all other appropriate medical options have been tried without sufficient improvement in pain control, SCS may result in a > 50% reduction in patient-reported pain. 4 The literature also provides evidence of the positive, symptomatic, long-term efficacy of SCS for the treatment of chronic pain of the trunk and/or limbs. 5 Although a significant body of literature exists to support these claims, few available, well-designed largescale studies have been conducted. Studies completed thus far have limitations in terms of either inhomogeneous patient assessment, researcher bias, or inconsistent followup. In addition, the recent introduction of rechargeable implantable pulse generator (IPG) technology has raised doubts on the usefulness of nonrechargeable devices. 6, 7 The following meta-analysis of 4 multicenter, prospective studies was designed to provide further evidence of the safety and efficacy of SCS in the management of pain of the trunk and/or limbs using a conventional IPG.
MATERIALS AND METHODS
Each of the 4 studies included in this meta-analysis was designed as a prospective, nonrandomized, multicentered study. Institutional review board approval was obtained for all sites before any patients were enrolled. After signing the informed consent, each patient underwent a baseline evaluation, followed by the SCS trial. Reflecting the current state of affairs in neuromodulation, there was no uniformity in the trialing technique, and the trial duration varied from site to site, ranging from very short testing (on the table) to up to 7 days. 8 If the patient reported a successful trial (defined by > 50% pain relief), 9-11 the patient was implanted with an SCS system comprising an IPG [Genesis/Genesis XP, Advanced Neuromodulation Systems (ANS), Plano, TX] and either percutaneous (Octrode or Quattrode, ANS) or surgical leads (Lamitrode, ANS).
Patient Selection
A patient was included in the studies if he/she fulfilled the following criteria: provided informed consent to participate in the study, had chronic pain of the trunk or limbs, all appropriate medical options had been tried without sufficient improvement in pain control (including opioids, nerve blocks, etc.), was 18 years of age or older, adequate pain relief demonstrated during intraoperative or trial screening, had already been preidentified by the investigator and had agreed to the SCS implant procedure, and had a baseline visual analog scale (VAS) score of Z6.
A patient was excluded from the study if he/she met any one of the following criteria: a systemic infection, had spinal column damage (eg, spinal instability) subarachnoid space blockage, tumors or abnormal computed tomography myelogram/magnetic resonance imaging that may prevent proper lead placement, a life expectancy of < 1 year, demand-type cardiac pacemakers, or already had a SCS system or implantable infusion pump in place. Patients in studies 3 and 4 were also excluded if they had a diagnosis of chronic pain as a result of a malignant disease, were pregnant or with child-bearing potential and not using adequate contraception as determined by the investigator, or had severe emotional or psychiatric conditions that could interfere with regimen compliance.
Outcome Measures
Efficacy was determined using 4 different pain rating scales, 2 quality-of-life (QoL) measurements, and a patient satisfaction question. The 4 pain rating scales included patient-reported pain relief, the numerical pain rating scale (NRS), the visual analog pain scale (VAS), and the short-form-McGill pain questionnaire SF-MPQ). Patientreported pain relief asked the patient to rate their percent of pain relief (using whole numbers), where 0% = no relief and 100% = complete relief. 12, 13 The NRS used an 11-point scale in which the patient was asked to rate their pain intensity from 0 (no pain) to 10 (pain as bad as you can imagine). [14] [15] [16] The VAS assessed pain intensity by having the patient to indicate a rating of their pain by drawing a vertical mark across the representative horizontal scale line to illustrate the pain experienced by them. 17 The SF-MPQ measured pain on a multidimensional scale. 18 Quality of life was measured using the Short Form-36 (SF-36) and a QoL question. The SF-36 is a 36-item tool for measuring health-related QoL from the patient's point of view. 19 In addition, patients were verbally asked to rate their QoL as "greatly improved," "improved," "stayed the same," "deteriorated," or "greatly deteriorated."
Statistical Analysis
Information on all individual patients was included in this meta-analysis. Results are presented both separately by study, and pooled if appropriate. Levene test was used to assess the equality of variance in the different studies. 20 The studies used in this meta-analysis were all nonrandomized, open-label studies with patients acting as their own control (without a separate control group). They were not blinded to the treatment as identification of paresthesia coverage was a necessary part of the treatment and precluded blinding. Because of this lack of a control group, classic meta-analysis techniques involving calculation of effect sizes are not feasible. Instead, a pooled noninferiority analysis was conducted. Descriptive statistics include means and SDs or frequencies as appropriate.
Primary Effectiveness Analysis
The primary effectiveness variable was patient-reported percent of pain relief. All patients reporting a value at the 3-month visit were included in the primary analysis. The primary analysis was based on a test of noninferiority to the accepted standard of 50% pain relief. In formal terms, the null (H0) and alternative (H1) hypotheses are as follows: H0: mr50%Àd versus H1: m > 50%Àd, where m is the population mean of patient-reported percent of pain relief and d is the noninferiority margin. For the purposes of this study, d was set at 10 percentage points. Therefore, if the null hypothesis is rejected, it will be concluded that the mean patient-reported percent of pain relief is noninferior to 50% to within 10 percentage points.
The primary analysis was conducted by placing a 1-sided lower 95% confidence bound on the mean of the individual patient-reported percent of pain relief. If this lower confidence bound is > 40% (50% Àd), the null hypothesis is rejected in favor of noninferiority.
Secondary Effectiveness Analysis
Patient-reported percent of pain relief was also assessed at 1 year to evaluate the long-term results. In addition, a success rate at 3 months and 1 year was calculated as the percent of patients reporting 50% pain relief or better. All study variables from each study are listed in Table 1 . Each of the secondary variables on efficacy and safety are summarized at each scheduled visit, and descriptive statistics are presented. Descriptive statistics included means and SDs or frequencies as appropriate. Secondary variables included NRS, SF-MPQ/VAS, pain relief rating, patient satisfaction, QoL improvement, and SF-36.
Safety Analysis
All adverse events (AEs) that occurred during the 4 studies are summarized and presented. The incidence proportion and prevalence rate are presented. Incidence proportions are calculated as the total number of events divided by the patient sample for the duration of the studies. Because patients may experience more than one AE, prevalence rates are also reported. Prevalence rates are calculated as the total number of patients with at least 1 event divided by the patient sample. AEs were also reported beginning at the time of implant to evaluate the short-term and long-term risk of complications.
RESULTS

Patient Disposition
There were a total of 300 implanted patients at 28 investigational sites participating in the 4 studies ( Table 2) . Of these, 195 were followed up for 1 year after implant and 105 were followed up for 6 months after implant. No site was included in more than one study. The safety summary included data from all 300 patients.
A total of 67 patients (22.3%) did not complete the total complement of their respective study visits. Therefore, data from a total of 252 patients were available for the 3-month analysis across all 4 studies and data from 173 patients were available for the 6-month and 1-year analyses for the long-term studies (studies 1 and 2).
Patient Primary Diagnosis
As per inclusion criteria, all 4 Genesis IPG studies included patients diagnosed with chronic intractable pain of the trunk and/or limbs. Table 3 shows the number and percentage of patients who aligned into specific diagnosis categories.
More than a half of the 300 study subject population aligned into 2 diagnosis categories, the largest of which were diagnosed with failed back surgery syndrome (50.7%; N = 152), a persistent and diffuse chronic lumbosacral pain, buttock pain, and lower extremity pain, followed secondarily by complex regional pain syndrome type 1 (reflex sympathetic dystrophy and type II (causalgia) (22.0%; N = 66). The remaining diagnosis categories were leg pain, pain (including radiculopathy and radiculitis) (16.3%; N = 49), peripheral neuropathy (3%; N = 9), and other diagnoses, which together constituted the remaining 8% (N = 24).
Pain Relief
The primary efficacy measure of this meta-analysis was patient-reported pain relief at 3 months. After assessing the equality of variance in patient-reported pain relief data with Levene test (P = 0.214), a pooled analysis was conducted. It revealed an overall mean pain relief of 60.5% (n = 252) at 3 months. The lower confidence bound on this mean is 57.19%. Because this bound is > 40%, the null hypothesis is rejected in favor of noninferiority to the accepted standard of 50% pain relief. The mean reported pain relief for each individual study and the pooled results are shown in Table 4 .
In addition to calculating mean patient-reported pain relief, the percentage of patients who reported pain relief of 50% or greater was tabulated for each individual study and overall (Table 5) . Results showed that overall, 75.4% of patients (190/252) reported 50% pain relief or better at the 3-month visit. Patient-reported pain relief was also collected at 6 months and at 1 year (for long-term studies 1 and 2). Results at 6 months showed that 73.4% (127/173) of the patients reported successful pain relief and 76.3% (132/ 173) reported successful pain relief at 1 year. Therefore, at each evaluation point of 3 months, 6 months, and 1 year, the overall results showed that > 70% of patients reported 50% or greater pain relief in each study.
Pain Intensity
Studies 1 and 2 collected information on pain intensity on an NRS, with 0 representing no pain and 10 representing the worst possible pain. Results (mean ± SD) from studies 1 and 2 and overall data are presented in Table 6 . The baseline NRS score averaged across the 2 studies was 7.5 ( ± 1.6). This score was reduced by 2.7 ( ± 2.6) at 3 months, by 2.5 ( ± 2.5) at 6 months, and 2.3 ( ± 2.5) at 1 year.
Short-term studies 3 and 4 documented VAS pain scores at baseline and at the 3-month evaluation to provide an index of overall pain intensity. The mean change in the VAS score from baseline to the 3-month visit was À5.1 ± 2.6 and À 4.7 ± 2.3, for study 3 and 4, respectively, showing a marked decrease in patient-reported pain intensity at the 3-month evaluation visit.
The SF-MPQ, which includes a VAS pain intensity scale, was used in study 1 and 2 at baseline and 1-year evaluations to measure pain on a multidimensional scale. Results showed that at the 1-year visit, the sensory component of pain decreased an average of 20.7% and 21.2%, the affective pain scores decreased by an average of 24.6% and 15.2%, the mean change in the Present Pain Index was À 1.4 and À1.6, and the mean change from baseline in the VAS was À3.5 cm and À3.3 cm for study 1 and 2, respectively.
Pain relief was also measured by a single global impression item. Patients were asked to rate their pain relief as "excellent," "good," "fair," "poor," and "not able to decide." At 3 months, in all 4 studies, 71.5% of patients (n = 180) rated their pain relief as "excellent" or "good." At 1 year, in the 2 long-term studies, 68.8% of patients (n = 119) rated their pain relief as "excellent" or "good."
Patient Satisfaction
Patient satisfaction with SCS therapy was measured by a single global impression item with the following possible responses: "very satisfied," "satisfied," "neither satisfied nor unsatisfied," "unsatisfied," and "very unsatisfied." At 3 months, 86.2% of patients in all 4 studies (n = 217) were satisfied or very satisfied with the therapy. At 1 year, 80.9% of patients in the 2 long-term studies (n = 140) were satisfied or very satisfied with the therapy.
Quality of Life
Improvement in quality of life was also measured by a single global impression item with the following possible responses: greatly improved, improved, neither improved or deteriorated, deteriorated, and greatly deteriorated. In all 4 studies, 77.9% of patients (n = 196) reported being improved or greatly improved at 3 months (Fig. 1) . In the 2 long-term studies, 75.0% of patients (n = 130) reported being improved or greatly improved at the 1-year follow-up (Fig. 2) . Patients in studies 1 and 2 completed the Short-Form-36 QoL Questionnaire at baseline and 1 year. Patients in studies 3 and 4 completed this assessment at baseline and 3 months. At 3 months, the mean scores in all 8 subscales increased over baseline (Table 7) . At 1 year, the mean scores in 7 of the 8 subscales increased and remained the same in 1 (Table 8) .
Complications
Complications for all 300 patients in the 4 studies were reviewed. A total of 190 events were reported in 117 patients during the course of all studies. Table 9 identifies all complications. It was possible for patients to have multiple AEs. Complication incidence was calculated as the number of events out of the total sample for all studies. Incidence represents the likelihood or risk that a patient will experience an AE, irrespective of whether they previously had one. The incidence rate of non-device-related AEs was 16.7%. The incidence of all device-related AEs was 46.7%.
The prevalence of AEs is defined as the percentage of patients who experienced at least 1 AE. In the 4 studies, 117 patients experienced at least 1 AE for an overall prevalence rate of 39.0%. The number of AEs per patient who experienced at least one of them ranged from 1 to 8, with a mean of 1.6. There were 15 patients with only non-device-related AEs. Excluding these patients, a total of 102 patients experienced at least 1 device-related AE for a prevalence of 34%. The most common AE identified involved undesirable changes in stimulation, with a total of 41 events for a 13.7% incidence reported across the 4 studies (N = 300). Pain, redness, or numbness at the electrode or the IPG site was less common, with a total of 27 events for a 9% incidence across the 4 studies (N = 300).
AEs were also grouped on the basis of time of occurrence. AEs occurring within 60 days of implant were considered short-term events and those occurring after 60 days were considered long-term events. Overall, 50% of AEs occurred within the first 60 days after implantation.
DISCUSSION
SCS is an established modality for the treatment of various pain syndromes. Since its introduction more than 40 years ago, SCS has become an accepted means for treatment of patients with medically intractable pain, including those with failed back surgery syndrome, complex regional pain syndrome types 1 and 2, and peripheral neuropathy. 21 In addition to wide clinical acceptance of SCS, multiple studies and meta-analyses have shown SCS to be both safe and effective. 5, [22] [23] [24] Two recent well-designed studies have looked at the outcome of SCS in a cohort of patients with Workers' Compensation claims. 25, 26 The studies found no benefits in terms of function and pain relief beyond 6 months of follow-up. The conclusion of these 2 studies came into scrutiny as only 25% of the SCS group underwent psychological evaluation and the study itself was financed by a state-governed insurance company. 27 Our study did not look specifically at the work status, as we were primarily investigating the overall efficacy, safety, and patient satisfaction. Very few studies, however, have addressed long-term effectiveness and patient satisfaction on the basis of multicenter prospective data collection.
The 4 prospective multicenter studies summarized in this meta-analysis were performed as postmarket evaluation of established SCS technology. They were performed in multiple centers across the United States, in a variety of practices by experienced implanters. It would be fair to assume that this group of 300 patients reflects the current practice of SCS use. A randomized-controlled trial of this magnitude in multiple centers is unlikely to occur at a practical level. The ethics of withholding a well-known pain-relieving therapy in patients with severe pain is questionable by most Institutional review boards today. Observational data with a large sample in many centers often show a very good correlation with randomized trials. 28 A recent review of studies on SCS 29 has summarized the requirements for future studies on SCS effects. Among other factors, it mentioned the need for evaluation of a broader range of outcomes, including pain, patient preference, function, work-related outcomes, cost, complications, and health-related QoL. 29 In the studies reviewed in our analysis, we were able to evaluate some of these criteria, including pain, patient preference, complications, and QoL. The work-related outcome and the costs were not assessed in a comprehensive manner, mainly because the majority of patients were not working and/or considering return to work due to retirement or prolonged disability, and the cost has already been a focus of other research studies.
From our analysis of effectiveness and safety, it seems that SCS with conventional (nonrechargeable) IPG provides > 50% reduction of pain to > 70% of those patients who had a successful SCS trial, and this improvement persists for 3, 6, and 12 months. In addition, about 70% of patients graded their pain improvement as good or excellent, and > 80% of patients were satisfied with their SCS treatment. The quality of life improved accordingly, with three quarters of patients describing QoL as improved or greatly improved. This phenomenon was confirmed by an increase in all 8 subscales of the QoL assessment instrument. The ranking order of patient satisfaction, over QoL, over absolute pain relief, further suggests that patients treated with SCS enjoy greater functionality rather than just reported reductions in pain intensities.
Furthermore, the majority of patients (61%) had no AEs during the entire follow-up period. Among these, 39% who had one or more AEs (117 of 300) and 12.8% (15 patients) had only non-device-related events. Of 140 device-related events that occurred in 102 patients, 89 included undesirable changes in stimulation that did not require anything other than reprogramming, diminishing or loss of pain relief and pain, redness, or numbness at the implant site. The frequency of the remaining 51 AEs, with an overall incidence of 17%, is consistent with previously reported studies. 22, 30 These included migration and breakage of the device, infection, seroma formation, cerebrospinal fluid leak, and wound dehiscence/erosion. Because most (but not all) of these issues require surgical intervention or hospital admission, the patients should be warned about these potential complications in advance.
The relative advantages of rechargeable versus nonrechargeable spinal cord stimulator IPGs have been debated. 6, 7 Although the patient's ability to recharge a spinal cord-stimulating system has been demonstrated, 7 an issue that our meta-analysis clearly supports is that SCS with a nonrechargeable IPG, such as Genesis/Genesis XP, is an excellent and time-tested modality that eliminates the need for periodic IPG recharging. A recent survey indicated that 23.3% of recharging sessions are described as problematic and that the majority of patients with rechargeable SCS systems would tolerate a larger IPG to relieve themselves of recharging. 31 Our meta-analysis supports the notion that SCS with a nonrechargeable IPG, such as Genesis/Genesis XP, is an excellent modality that eliminates the need for recharging sessions. Although rechargeable IPGs are associated with an initial increased expense compared with nonrechargeable units, rechargeable IPGs have been recommended when IPG longevity is likely to be short (ie, < approximately 4 years). 32 However, the availability of nonrechargeable devices provides an excellent alternative to more expensive rechargeable systems, particularly in situations with lower SCS power requirements and in older patients who seem to feel that recharging is not worth added battery life 31 or when only intermittent use of SCS is required. The data presented here confirm the impression of the authors and other experienced implanters regarding the validity of considering nonrechargeable IPGs for the patients with lower SCS power requirements and those with anticipated difficulties in recharging SCS devices. 
